Featured Story

Quest's Q2 revenue dips as it absorbs restructuring and M&A expenses

Quest Diagnostics saw its net income drop and earnings per share decline during the 2014 second quarter, as the company absorbed costs stemming from restructuring and M&A integration expenses. The New Jersey diagnostics giant has also adjusted full-year revenue projections for 2014.

Quest forks over milestone payments to French Dx company in development deal

Quest Diagnostics' partnership deal with a state-of-the-art French company is showing signs of paying off.

A missile, a plane crash and a profound loss to AIDS research

Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.

GeneCentric grabs $5M Series A to advance testing for personalized cancer treatments

Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.

PA startup's Series B will bring arthroscopic Dx needle through FDA clearance and launch

A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.


From Our Sister Sites


Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.


Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly didn't cause the decline, with newcomers Perjeta and Kadcyla helping power the group with especially noteworthy revenue gains.